600062.SHG China Resources Double-Crane Pharmaceutical Co Ltd
- Market cap
- CNY 16.7B
- P/E
- 10.6x
- P/B
- 1.34x
- ROE
- 13.6%
- Dividend yield
- 4.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600062.SHG undervalued?
Graham number600062.SHG trades 20.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Resources Double-Crane Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for China Resources Double-Crane Pharmaceutical Co Ltd yet.
China Resources Double-Crane Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Resources Double-Crane Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People's Republic of China. China…
Full company profileChina Resources Double-Crane Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China Resources Double-Crane Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.49B | 6.42B | 8.23B | 9.38B | 8.50B | 9.11B | 9.63B | 11.3B | 11.2B | 11.0B | 10.8B |
| Gross Profit | 2.90B | 3.67B | 5.20B | 5.93B | 5.35B | 5.06B | 5.32B | 6.41B | 6.38B | 6.38B | 6.16B |
| Operating Income | 847M | 1.06B | 1.19B | 1.26B | 1.23B | 1.14B | 1.43B | 1.88B | 1.83B | 1.86B | 1.76B |
| EBITDA | 1.23B | 1.39B | 1.54B | 1.63B | 1.59B | 1.58B | 1.99B | 2.62B | 2.60B | 2.73B | 2.06B |
| Net Income | 714M | 843M | 969M | 1.06B | 1.01B | 936M | 1.18B | 1.67B | 1.63B | 1.65B | 1.69B |
| EPS | 0.68 | 0.81 | 0.93 | 1.01 | 0.96 | 0.90 | 1.14 | 1.63 | 1.58 | 1.59 | 1.63 |
| Balance Sheet | |||||||||||
| Total Assets | 8.24B | 9.44B | 10.3B | 11.3B | 12.4B | 13.7B | 14.5B | 15.4B | 16.7B | 17.0B | 19.1B |
| Total Liabilities | 1.20B | 1.59B | 2.40B | 2.60B | 3.04B | 3.20B | 3.75B | 3.64B | 5.57B | 4.51B | 5.77B |
| Shareholders' Equity | 6.69B | 7.46B | 7.84B | 8.60B | 9.29B | 9.91B | 10.0B | 11.1B | 10.4B | 11.6B | 12.5B |
| Cash & Short-term Investments | 1.49B | 1.25B | 1.98B | 2.60B | 3.26B | 3.64B | 2.83B | 3.46B | 2.85B | 2.42B | 2.12B |
| Total Debt | - | 322K | 82.0M | 64.9M | 6.64M | 64.9M | 265M | 59.9M | 1.18B | 1.16B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 771M | 1.19B | 1.47B | 1.44B | 1.36B | 1.34B | 1.34B | 1.65B | 1.83B | 1.49B | - |
| Capital Expenditure | 110M | 155M | 229M | 242M | 348M | 492M | 526M | 614M | 637M | 620M | 494M |
| Free Cash Flow | 661M | 1.03B | 1.24B | 1.20B | 1.01B | 849M | 816M | 1.03B | 1.19B | 870M | 985M |
| Ratios | |||||||||||
| ROE | 10.7% | 11.3% | 12.4% | 12.3% | 10.8% | 9.4% | 11.8% | 15.1% | 15.6% | 14.2% | 13.6% |
| ROA | 8.7% | 8.9% | 9.4% | 9.4% | 8.1% | 6.8% | 8.1% | 10.8% | 9.8% | 9.7% | 8.9% |
| Net Profit Margin | 13.0% | 13.1% | 11.8% | 11.2% | 11.8% | 10.3% | 12.3% | 14.8% | 14.5% | 15.0% | 15.8% |
| Debt to Equity | - | 0.00x | 0.01x | 0.01x | 0.00x | 0.01x | 0.03x | 0.01x | 0.11x | 0.10x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China Resources Double-Crane Pharmaceutical Co Ltd dividends
- Dividend yield
- 4.28%
- Forward dividend
- 0.48 CNY
- Payout ratio
- 43.5%
- Ex-dividend date
- Jul 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 716M | 0.69 | 43.5% |
| 2024 | CNY 1.48B | 1.44 | 90.9% |
| 2023 | CNY 300M | 0.29 | 18.0% |
| 2022 | CNY 799M | 0.77 | 67.7% |
| 2021 | CNY 303M | 0.29 | 32.3% |
| 2020 | CNY 317M | 0.30 | 31.6% |
| 2019 | CNY 291M | 0.28 | 27.6% |
| 2018 | CNY 91.1M | 0.09 | 9.4% |
| 2017 | CNY 194M | 0.19 | 23.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Aug 16, 2018.
Who owns China Resources Double-Crane Pharmaceutical Co Ltd
- Insiders 62.69%
- Institutions 1.58%
- Public & others 35.73%
- Shares outstanding 1.04B
- Free float 404M
China Resources Double-Crane Pharmaceutical Co Ltd company profile
- Company name
- China Resources Double-Crane Pharmaceutical Co Ltd
- Ticker
- 600062.SHG
- ISIN
- CNE000000Q94
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 6, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 13,184
- Fiscal year end
- December
- Address
- No. 1, Lize East 2nd Road, Beijing, China, 100102
- Phone
- 86 10 6474 2227
- Website
- dcpc.com
About China Resources Double-Crane Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiary of Beijing Pharmaceutical Group Co., Ltd.
China Resources Double-Crane Pharmaceutical Co Ltd management
6- Mr. Qian ZhaoPresident & Director · born 1982
- Mr. Wen Hao HuangChief Financial Officer · born 1984
- Mr. Ju LiuBoard Secretary & VP · born 1973
- Mr. Chao ManVice President · born 1971
- Mr. Hekai TanVice President · born 1973
- Chang Jiu YuAccounting Supervisor